Trial Profile
A Phase 1b Study to Assess the Safety of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 24 Jun 2020 Results of a genomic analysis using (FFPE) TGCT specimens from six clinical studies: NCT01004861, NCT02777710, NCT01217229, NCT01525602, NCT01790503 and NCT02452424 assessing CSF1 genetic alterations and rearrangements presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 04 Apr 2018 Status changed from active, no longer recruiting to completed.
- 15 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.